Masimo Corp Stock Price, News & Analysis

Masimo (NASDAQ: MASI) announced a study published in the European Journal of Pediatrics, highlighting the effectiveness of its EMMA^® Portable Capnograph for monitoring mechanically ventilated preterm infants. Conducted by Dr. Masashi Hotta and colleagues in Japan, the study involved 40 neonates and found that 80% in the EMMA group maintained appropriate carbon dioxide levels compared to 42% in a control group. The research emphasizes EMMA's potential in neonatal care, although it currently lacks FDA clearance for neonates.

Masimo (NASDAQ: MASI) announced that its Founder and CEO, Joe Kiani, has been appointed by President Biden to the President’s Council of Advisors on Science and Technology (PCAST). This council aims to provide the President with scientific advice on various pressing issues, including public health and climate change. The PCAST comprises 30 diverse members with extensive expertise in science and technology. Kiani expressed enthusiasm about collaborating with this distinguished group to enhance healthcare and innovation.

Masimo (NASDAQ: MASI) announced the CE marking and launch of its innovative rainbow® SuperSensor™ in Europe, designed for single-patient use. This advanced sensor can monitor 12 physiological parameters noninvasively, including SpO₂, total hemoglobin, and respiration rate. The SuperSensor enhances continuous monitoring capabilities, allowing clinicians to assess patients' conditions more accurately. With proven effectiveness in improving patient outcomes, this technology aims to bolster patient safety and streamline care in critical settings.

Masimo (NASDAQ: MASI) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 4:15 p.m. ET. A live webcast will be available on the company's website, with a replay following the event. Masimo is a leader in medical technology, known for its innovative monitoring solutions including Masimo SET^® pulse oximetry, which has been validated in over 100 studies. The technology aims to enhance patient outcomes and minimize healthcare costs, with significant usage across major hospitals.

Masimo (NASDAQ: MASI) announced a study revealing that the Oxygen Reserve Index (ORi) may provide early warnings for hypoxemia during endotracheal intubation (ETI) in ICU patients. Conducted by researchers at Centre Hospitalier Universitaire in France, the study showed a median of 81 seconds between ORi decrease and oxygen saturation drop, allowing for preventive actions. The study concluded that a higher ORi during preoxygenation is independently protective against hypoxemia. However, ORi lacks FDA clearance in the U.S.

Masimo (NASDAQ: MASI) has announced its commitment to raising awareness about opioid overdose risks on International Overdose Awareness Day (August 31). The initiative is in response to alarming statistics, with opioid-related deaths in England and Wales reaching their highest levels since 1993. The company is launching an educational website, www.OpioidSafety.org, to provide crucial information on the dangers of opioid use, even when prescribed. Collaborating with the Penington Institute, Masimo will fund research on opioid overdoses, with the first report expected in 2022.

Masimo (NASDAQ: MASI) has launched the Masimo SafetyNet Alert in Western Europe, an advanced blood oxygen monitoring system designed for home use, particularly for patients taking opioids. This system utilizes innovative Signal Extraction Technology to monitor blood oxygen saturation (SpO₂) and pulse rate. It can alert users and emergency contacts in case of dangerous drops in oxygen levels, potentially preventing fatal overdoses. Masimo SafetyNet Alert aims to improve patient safety and reduce opioid-related deaths.

Masimo (NASDAQ: MASI) highlights the findings from a recent whitepaper by the Society for the Advancement of Patient Blood Management (SABM), advocating for continuous hemoglobin (Hgb) monitoring to enhance patient care in critical settings. The whitepaper cites more than a decade of research and emphasizes that real-time Hgb data aids clinicians in making timely decisions, ultimately improving outcomes, reducing blood transfusions, and decreasing costs. Continuous monitoring can lead to significant reductions in post-surgery mortality rates across multiple countries.

Masimo (NASDAQ: MASI) published a study in the Turkish Journal of Emergency Medicine, highlighting the correlation between the Pleth Variability Index (PVi) and volume changes in hemodialysis patients. Conducted by researchers at Kecioren Training and Research Hospital, the study involved 60 patients and demonstrated that PVi increased significantly after fluid removal, indicating its potential for monitoring volume status in critically ill patients. While PVi shows promise, its accuracy in predicting fluid responsiveness can be variable and should not solely drive fluid management decisions.